A prospective, multicenter, single-arm clinical study of haploid hematopoietic stem cell transplantation combined with umbilical cord blood transfusion in the treatment of hematological malignancies

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062553

Enrollment

Unknown

Registered

2022-08-11

Start date

2022-08-07

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

Experimental group:haploid hematopoietic stem cell transplantation combined with umbilical cord blood transfusion

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with hematological malignancies; 2. Scheduled haploid hematopoietic stem cell transplantation and donor age > 40 years; 3. Subjects aged 18-65 years; 4. Eastern Cooperative Oncology Group (ECOG) performance status <= 2. 5: Adequate liver and kidney function (creatinine < 1.5ULN, BUN < 1.5ULN, ALT < 2ULN, AST < 2ULN, total bilirubin < 1.5ULN) 6: Able to comply with study visit schedule and understand and comply with all protocol requirements 7: Able and willing to sign informed consent

Exclusion criteria

Exclusion criteria: 1. Salvage haploid hematopoietic stem cell transplant recipients; 2. Patients with allergic reactions to the drugs used in this study or similar drugs; 3. Pregnant or lactating women; 4. Received any investigational drug within 28 days prior to the first date. 5: Any active malignancy, except focal nonmetastatic squamous cell or basal cell skin cancer or carcinoma in situ patients with a history of malignancy that has been cured (eg, no evidence of malignancy for at least 2 years) may be enrolled 6: Presence of other clinically significant, poorly controlled systemic infection (viral, bacterial, or fungal) requiring treatment 7: Patients with severe organ dysfunction or diseases, such as heart, liver, kidney and lung and other serious diseases and dysfunction or with any other medical diseases that may adversely affect the subject 's participation in the study in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
Cumulative Incidence of Grade II-IV GVHD From Day 1 to Day 100 Post-Transplant;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactHongyan Tong/Jiejing Qian

hongyantong@aliyun.com+86 13958122357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026